Canadian non-dilutive grant money arrives later than you may think
A founder I worked with a couple of years ago told me that she had "about $250,000 in non-dilutive funding lined up" that would activate as soon as she found a lead investor. She was pleased, and she had every right to be — she had done the work, the applications were strong, and the money was genuinely coming.
Then I asked six months later whether it had landed in her bank account, and the conversation changed shape. It still wasn't there. She was discouraged.
Because here is the thing nobody puts on the programme landing page: most Canadian non-dilutive funding pays you back rather than paying you forward, or it's gated as a matching fund. You spend first. You claim after. The money is real, the money is significant, and the money is not available on the Thursday you need to make payroll.
I've watched this catch out smart people repeatedly, and I've been caught by a version of it myself. There is a particular flavour of optimism that sets in when a government programme says "up to $500,000," and it is not a flavour that survives contact with the phrase "eligible expenditures, reimbursed quarterly." I get it, I really do. These programs don't want to be handouts, and they want to make sure entrepreneurs have "skin in the game". That's why they are matching funds and reimbursements. They are extremely valuable for startups that already have revenue and/or a runway from early investments. They make runway dollars go farther and are a competitive advantage. But if you are just getting started, at angel and pre-seed stage, it's important to understand how they work.
The three big ones: SR&ED, IRAP, and Mitacs.
SR&ED — the Scientific Research and Experimental Development tax credit — refunds up to roughly 35% of eligible R&D spending for Canadian-controlled private corporations. It is the single largest source of innovation funding in the country and you can claim it with no revenue at all.
The timing: you claim it when you file your corporate taxes. So the money that arrives this year is repaying work you paid someone for last year. It is excellent. It is also, structurally, always one lap behind you. Great when you are already up and running. Not helpful when you are pre-revenue, unless you have other funds to pay for the work you need.
IRAP — the National Research Council's Industrial Research Assistance Program — reimburses a share of the salaries of technical staff working on an approved project. You get an Industrial Technology Advisor (ITA) assigned to your company, which is worth quite a lot on its own: ITAs tend to know every other funding door in your region.
The timing: reimbursement. You pay the salaries, you submit the claim, the money follows. And SR&ED stacks on top, which super helpful. However, once again you have to pay up front.
Mitacs — internship funding that pairs you with academic researchers. Genuinely good value, and the intellectual property arrangements are more founder-friendly than most people expect.
The timing: it needs a university research partner and, in the standard structure, $7,500 of your own cash per internship unit. So it is matching money, not free money. If you have an academic collaborator — or want an excuse to acquire one — it's one of the better deals available. If you have neither a partner nor the match, it isn't a real option this quarter, however good it looks in a slide.
Beyond those three, there's a provincial layer that varies enormously depending on where you're incorporated, but that genuinely do offer non-dilutive options for early-stage founders. For more information, see my Founder - Funder Translator #3 post.
So: grants first, or investors first? Or nest egg first?
All of the above. Start the paperwork early.
Non-dilutive applications cost you time rather than equity, and a founder who has already been diligenced by IRAP walks into an investor meeting with an external party's homework on the table. That is not nothing. Investors read "we've been approved for X" as a signal that somebody with no upside checked our claims.
But the trap is now obvious when you say it plainly: the reimbursement model means you need cash before the free cash shows up. SR&ED repays last year. IRAP repays last quarter. Mitacs wants a cheque up front.
That gap — between the spending and the reimbursing — is the first big challenge for any new founder.
The gap is precisely why you've hopefully saved some money ahead of time, why you don't quit your day job in the earliest days, and hopefully why you've had a real discussion with your family about the costs of funding your startup until it is either customer- or investor-funded.
The gap is what your first equity round is for, and why you need real paying customers as soon as you can possibly get them.
The gap is why founders work so hard in the early days to get as much traction as possible. They do it BOTH to help pay the bills and to convince investors that there is a market for what they are building. See this post for more on investor traction expectations.
The gap is always longer and deeper than you think it will be. Just sayin'.
Which reframes the sequencing question. It isn't "grants or investors." It's: how much do I need to have in order to afford the money I've been awarded? That's an unromantic sentence, but it's a useful perspective.
Canadian non-dilutive grant money arrives later than you may think
Before you build the plan, get two facts about every programme on your list, and get them in writing rather than from a summary:
Up front, reimbursement, or tax credit? These are three genuinely different products wearing similar language.
What do you have to bring? Cash match, academic partner, in-province spending, minimum headcount.
Everything else — the maximum award, the success rate, the inspiring case study on the programme website — matters less than those two.
Introducing My Capital Roadmap and the Non-Dilutive Sprint
I got tired of watching founders discover the fine print at the worst possible moment. I got tired of hearing the same questions from founders on repeat. So I built a tool to help.
I was particularly motivated by the plight of health and life science founders in Canada, who often have the longest road before they can generate sales revenue. I plan to expand beyond those sectors eventually, but the first version is for them. It currently helps founders across the country filter 61 non-dilutive programmes, for the ones most applicable to them. The goal is to save founders hours of research and wasted effort. The matches are AI-assisted, but with a human in the loop. I thought this would be an easy vibe-coding project. It was not. More on that later. If it's useful, it's at My Capital Roadmap. The Non-Dilutive Sprint is $49 and should help founders zero in quickly on programmes that are right for them. The full Capital Roadmap includes everything in the Non-Dilutive Sprint, plus a stage-appropriate sequence of possible investors. I have been beta testing this with a cohort of healthtech companies from Ontario and getting great feedback. Now it's ready for wider use. The more people use it, the better it will get.
The money in Canada to support entrepreneurship is more plentiful than founders think and slower than they hope. Plan for the second half of that sentence, and the first half becomes a great deal more useful. _________________ What are your thoughts? Share them in the comments. If you liked this post, please send it to a friend. Want some help with your own startup and fundraising process? Please reach out.
Landon Steele is a startup consultant, angel investor, and advisor to early-stage founders. She is based in Vancouver, BC. She works with founders and the ecosystems that fund them across Canada and the US. Learn more at steeleconsultinggroup.com
Comments